scholarly journals Lipoprotein-Inspired Nanocarrier Composed of Folic Acid-Modified Protein and Lipids: Preparation and Evaluation of Tumor-Targeting Effect

2020 ◽  
Vol Volume 15 ◽  
pp. 3433-3445
Author(s):  
Mengmeng Han ◽  
Xiaoman Ji ◽  
Jianfei Li ◽  
Zhiming Ge ◽  
Bin Luo ◽  
...  
Keyword(s):  
Folic Acid ◽  
Tumor Targeting ◽  
Targeting Effect ◽  
Preparation And Evaluation

scholarly journals Tumor Targeting Effect of Triphenylphosphonium Cations and Folic Acid Coated with Zr-89-Labeled Silica Nanoparticles

Molecules ◽  
2020 ◽  
Vol 25 (12) ◽  
pp. 2922
Author(s):  
Gun Gyun Kim ◽  
Jun Young Lee ◽  
Pyeong Seok Choi ◽  
Sang Wook Kim ◽  
Jeong Hoon Park
Keyword(s):  
Folic Acid ◽  
Membrane Potential ◽  
Silica Nanoparticles ◽  
Cancer Cells ◽  
Tumor Targeting ◽  
Particle Surface ◽  
Silanol Group ◽  
Radiochemical Yield ◽  
Drug Carriers ◽  
Targeting Effect

In this study, we investigated the tumor targeting effect in cancer cells using triphenylphosphonium (TPP) cations, which are accumulated by differences in membrane potential, and folic acid (FA), which is selectively bound to overexpressed receptors on various cancer cells. We used Food and Drug Administration (FDA)-approved silica nanoparticles (SNPs) as drug carriers, and SNPs conjugated with TPP and FA (STFs) samples were prepared by introducing different amounts of TPP and FA onto the nanoparticle surfaces. STF-1, 2, 3, 4 and 5 are named according to the combination ratio of TPP and FA on the particle surface. To confirm the tumor targeting effect, 89Zr (t1/2 = 3.3 days) was coordinated directly to the silanol group of SNP surfaces without chelators. It was shown that the radiochemical yield was 69% and radiochemical purity was >99%. In the cellular uptake evaluation, SNPs with the most TPP (SFT-5) and FA (SFT-1) attached indicated similar uptake tendencies for mouse colon cancer cells (CT-26). However, the results of the cell internalization assay and measurement of positron emission tomography (PET) images showed that SFT-5 had more affinity for the CT-26 tumor than other samples the TPP ratio of which was lower. Consequently, we confirmed that TPP ligands affect target cancer cells more than FA, which means that cell membrane potential is significantly effective for tumor targeting.

Folic acid mediated tumor targeting effect observed by fluorescent imaging

2012 ◽  
Vol 42 (8) ◽  
pp. 1172-1178
Author(s):  
Jun YUE ◽  
Rui WANG ◽  
XiuLi HU ◽  
XiaBin JING ◽  
Shi LIU
Keyword(s):  
Folic Acid ◽  
Tumor Targeting ◽  
Fluorescent Imaging ◽  
Targeting Effect

scholarly journals Phosphorylcholine oligomer-grafted graphene oxide for tumor-targeting doxorubicin delivery

RSC Advances ◽  
2017 ◽  
Vol 7 (66) ◽  
pp. 41675-41685 ◽  
Author(s):  
Yu Qin ◽  
Changyu Wang ◽  
Yun Jiang ◽  
Tao Liu ◽  
Jianyong Yang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Graphene Oxide ◽  
Folic Acid ◽  
Tumor Targeting ◽  
Doxorubicin Delivery

Phosphorylcholine oligomer-grafted, folic acid-labeled and doxorubicin-loaded graphene oxide was found to be a potential versatile platform for biomarker-directed drug delivery with optimal biocompatibility.

Effective tumor-targeted delivery of etoposide using chitosan nanoparticles conjugated with folic acid and sulfobetaine methacrylate

RSC Advances ◽  
2016 ◽  
Vol 6 (94) ◽  
pp. 91192-91200 ◽  
Author(s):  
Song Hua ◽  
Jiahua Yu ◽  
Jun Shang ◽  
Haowen Zhang ◽  
Jie Du ◽  
...  
Keyword(s):  
Folic Acid ◽  
Targeted Delivery ◽  
Tumor Targeting ◽  
Chitosan Nanoparticles

FA–CS(VP-16)-g-PSBMA nanoparticles were synthesized and showed effective tumor-targeting properties and promising anti-tumor capacity in vivo.

Multifunctional nanosheets based on folic acid modified manganese oxide for tumor-targeting theranostic application

2015 ◽  
Vol 27 (2) ◽  
pp. 025101 ◽  
Author(s):  
Yongwei Hao ◽  
Lei Wang ◽  
Bingxiang Zhang ◽  
Hongjuan Zhao ◽  
Mengya Niu ◽  
...  
Keyword(s):  
Folic Acid ◽  
Manganese Oxide ◽  
Tumor Targeting

scholarly journals Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Xuezhi Cao ◽  
Yong Liang ◽  
Zhenxiang Hu ◽  
Huiyu Li ◽  
Jiaming Yang ◽  
...  
Keyword(s):  
Tumor Microenvironment ◽  
Immune Responses ◽  
Half Life ◽  
Tumor Targeting ◽  
Type I Interferon ◽  
Therapy Resistance ◽  
Type I ◽  
Type I Ifn ◽  
Targeting Effect

AbstractType I interferon is promising in treating different kinds of tumors, but has been limited by its toxicity, lack of tumor targeting, and very short half-life. To target tumors, reduce systemic toxicity, and increase half-life, here we engineer a masked type I IFN-Fc (ProIFN) with its natural receptor connected by a cleavable linker that can be targeted by tumor-associated proteases. ProIFN has a prolonged serum half-life and shows an improved tumor-targeting effect. Interestingly, ProIFN-treated mice show enhanced DC cross-priming and significant increased CD8+ infiltration and effector function in the tumor microenvironment. ProIFN is able to improve checkpoint blockade efficacy in established tumors, as well as radiation efficacy for both primary and metastatic tumors. ProIFN exhibits superior long-term pharmacokinetics with minimal toxicity in monkeys. Therefore, this study demonstrates an effective tumor-activating IFN that can increase targeted immunity against primary tumor or metastasis and reduce periphery toxicity to the host.

Surface Modification of Magnetite Nanoparticles with Doxorubicin and RGD Peptide and their Biomedical Application

2007 ◽  
Vol 342-343 ◽  
pp. 793-796 ◽  
Author(s):  
K.M. Kamruzzaman Selim ◽  
Mi Jin Park ◽  
Hong Mi Kim ◽  
Inn Kyu Kang
Keyword(s):  
Magnetite Nanoparticles ◽  
Tumor Targeting ◽  
Biomedical Application ◽  
Rgd Peptide ◽  
Intracellular Uptake ◽  
Culture Experiment ◽  
Targeting Delivery ◽  
Surface Modified ◽  
Targeting Effect ◽  
Cell Culture Experiment

In the present study, superparamagnetic maltotrionic acid-coated magnetite nanoparticles (MAM) were surface modified with doxorubicin (DOX) and RGD peptide to improve their intracellular uptake, ability to target tumor cells and antitumer effect. RGD was added to the distal end of MAM aiming to construct an enhanced tumor targeting delivery system. To test its targeting effect, DOX, a widely used anticancer drug, was immobilized on the RGD-modified magnetite nanoparticles. DOX-coated magnetite nanoparticles were also prepared as a control. KB cell culture experiment showed that both DOX-modified nanoparticles and DOX-RGD peptide-modified magnetite nanoparticles (DRMAM) were internalized into the cells. But the uptake amount of DRMAMs was higher than that of DOX-modified nanoparticles. This result indicates that DRMAMs have a great potential to be used as contrast agent and antitumor medicine.

Sign in / Sign up

Export Citation Format

Share Document